LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Затворен

Сектор Здравеопазване

59.21 -2.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

59.01

Максимум

59.43

Ключови измерители
By Trading Economics
Приходи	16M 93M
Продажби	35M 231M
P/E Средно за сектора	21.73 103.001
EPS	0.91
Марж на печалбата	40.366
Служители	373
EBITDA	22M 143M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+1.89 upside

Дивиденти
By Dow Jones
Следващи печалби	4.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	262M 8.1B
Предишно отваряне	62.06
Предишно затваряне	59.21

Настроения в новините

By Acuity

50%

114 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 62.05 Подкрепа & съпротива

Halozyme Therapeutics Inc Графика

Свързани новини

6.09.2024 г., 22:41 ч. UTC

Пазарно говорене

KinderCare and StandardAero File for IPOs -- Market Talk

6.09.2024 г., 21:18 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6.09.2024 г., 21:05 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 20:39 ч. UTC

Печалби

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6.09.2024 г., 20:35 ч. UTC

Топ новини

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6.09.2024 г., 20:34 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6.09.2024 г., 20:11 ч. UTC

Топ новини

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6.09.2024 г., 19:51 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6.09.2024 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Hold Gains -- Market Talk

6.09.2024 г., 19:14 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6.09.2024 г., 19:01 ч. UTC

Пазарно говорене

Gold Slips on Prevailing Uncertainty -- Market Talk

6.09.2024 г., 18:27 ч. UTC

Топ новини

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6.09.2024 г., 18:25 ч. UTC

Пазарно говорене

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6.09.2024 г., 18:15 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6.09.2024 г., 18:12 ч. UTC

Топ новини

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6.09.2024 г., 17:44 ч. UTC

Пазарно говорене

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Пазарно говорене

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Топ новини

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6.09.2024 г., 17:27 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in August -- Market Talk

6.09.2024 г., 16:36 ч. UTC

Пазарно говорене

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6.09.2024 г., 16:35 ч. UTC

Печалби

Горещи акции

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6.09.2024 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Печалби

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Halozyme Therapeutics Inc Прогноза

Ценова цел

By TipRanks

1.89% нагоре

12-месечна прогноза

Среден 60.33 USD 1.89%

Висок 72 USD

Нисък 51 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Halozyme Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Halozyme Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 62.05Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

114 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.